Hematopoietic Stem Cells Transplantation Market size was over USD 3.05 billion in 2024 and is expected to exceed USD 10.16 billion by the end of 2037, growing at over 9.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of hematopoietic stem cells transplantation is evaluated at USD 3.29 billion.
The reason behind the growth is impelled by the rising prevalence of leukemia. Hematopoietic stem cell transplantation can be used to treat certain cancers, including leukemia, as stem cells aid in immune system restoration and the stimulation of new bone marrow development that may benefit patients to regenerate healthy bone marrow. In 2020, there were more than 474,510 new cases of leukemia reported globally.
The growing advancements in stem cell transplantation technology are believed to fuel the market growth. For instance, in February 2023, Lund University in Sweden discovered that stem cells have shown promise in treating the inflammation that underlies heart failure as it was found that patients receiving the treatment had more than 55% lower risk of heart attack or stroke, and the benefits rose to over 70% in patients with high inflammation since the treatment may decrease plaque instability.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.7% |
|
Base Year Market Size (2024) |
USD 3.05 billion |
|
Forecast Year Market Size (2037) |
USD 10.16 billion |
|
Regional Scope |
|
Transplant Type (Allogeneic, Autologous)
The autologous segment is estimated to account for 58% share of the global hematopoietic stem cells transplantation market in the coming years owing to the rising prevalence of cancer. The incidence of cancer increases sharply with age, most likely because certain malignancies have accumulating risks that climb with age. The primary driver of the general increase in cancer risk is our advancing age, adoption of a Western lifestyle, poor eating practices, dairy products, processed foods, food additives, non-vegetarian diets, chemical pollution, constipation, and physical inactivity. This has significantly led to an increase in the demand for autologous hematopoietic stem cell transplantation as it is used to treat certain types of cancer.
An autologous stem cell transplant also known as autologous bone marrow transplant replaces malfunctioning bone marrow with healthy blood stem cells from within the body that are utilized for patients whose illnesses require heavy dosages of radiation and chemotherapy whereby the damaged bone marrow is partially restored with the use of an autologous stem cell transplant. According to estimates, there were more than 609,810 cancer deaths and over 1,957,310 new cancer cases in the US in 2023.
Application (Peripheral Blood Stem Cell Transplant, Bone Marrow Transplant, Cord Blood Transplant)
Hematopoietic stem cells transplantation market from the blood stem cell transplant segment is set to garner a notable share shortly. A blood stem cell transplant is a surgical technique that involves the transplantation of peripheral blood stem cells, cord blood, and bone marrow to introduce healthy blood-forming cells from a donor into the patient's circulation, where they start to proliferate and produce platelets, red blood cells, and white blood cells.
End-User (Hospitals, Specialty Centers)
The hospitals segment is anticipated to gain a robust market share of 54% during the forecast timeframe. The treatment for hematopoietic stem cell transplantation is usually done in hospitals as they offer a whole spectrum of transplant services and the availability of skilled medical professionals.
Our in-depth analysis of the global hematopoietic stem cells transplantation market includes the following segments:
|
Transplant Type |
|
|
Application |
|
|
Disease Indication |
|
|
End-User |
|
North American Market Forecast
Hematopoietic stem cells transplantation market in North America is predicted to account for the largest share of 40% by 2037 impelled by the presence of major key players in the region. This has led to increasing mergers and acquisitions in the region which has led to the development of advanced hematopoietic stem cell transplantation treatment. For instance, in 2021, Avalon GloboCare Corp. acquired Hebei Senlang Biotechnology Co. Ltd. to create a strong pipeline that comprises over 14 universal, autologous, "off-the-shelf" CAR-T and CAR-γδT cell therapy candidates to enhance cutting-edge cell/gene engineering and exclusive cell expansion knowledge with exceptional therapeutic efficacy and safety profile.
APAC Market Statistics
The APAC hematopoietic stem cells transplantation market is estimated to be the second largest, during the forecast timeframe led by growing medical tourism. India is becoming a major destination for medical tourism, providing people from all over the world with high-quality healthcare at reasonable prices, and cutting-edge medical facilities. India has become a popular location for people undergoing stem cell transplants aided by the availability of cutting-edge facilities, skilled medical personnel, and cutting-edge technology that attracts medical tourists who may not be able to pay or obtain them in their native countries.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?